First-Line Zongertinib in Advanced HER2-Mutant NSCLC: A New Targeted Standard Begins to Take Shape
oncodaily - For years, HER2-mutant non-small-cell lung cancer sat in an uncomfortable place in thoracic oncology. It was clearly an oncogene-driven disease, but unlike EGFR-mutant or ALK-rearranged NSCLC, it did not have […]
AI Summary: Clinical trial data show zongertinib delivers strong antitumor activity as a first‑line treatment for patients with advanced HER2‑mutant non‑small cell lung cancer, positioning the drug as a potential new targeted standard. Robust response rates in previously untreated patients are prompting clinicians to rethink initial treatment choices while attention turns to long‑term safety and access.
FDA updates mifepristone safety study status
Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…
AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.
First-in-human trial primes immune system to accept donor livers
medicalxpress - UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a unique "immune priming" therapy.
AI Summary: A first‑in‑human study reports a novel immune‑priming approach that enabled three liver transplant recipients to stop standard lifelong immunosuppression. The intervention appears to induce tolerance to donor tissue, reducing dependence on anti‑rejection drugs and their toxic side effects, offering a potential shift in transplant management if larger trials confirm these early results.
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…
AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.
ESMO 2026 Guideline: Redefining the Management of Metastatic Colorectal Cancer
oncodaily - Metastatic colorectal cancer (mCRC) represents a complex and biologically diverse disease in which treatment decisions increasingly depend on molecular characteristics, disease burden, and patient-specific factors. While therapeutic options have expanded …
AI Summary: The European Society for Medical Oncology released updated clinical practice guidelines for metastatic colorectal cancer, redefining diagnostic pathways, systemic therapy sequencing, and follow‑up standards. The guidance incorporates recent targeted and immunotherapy evidence to recommend practical treatment algorithms, prompting oncology centers to update protocols and payers to reassess coverage as clinicians translate recommendations into routine care.
FDA approves Travere's Filspari as first drug for the kidney disease called FSGS
Nicole DeFeudis / endpoints - The FDA expanded the label for Filspari on Monday to add another kidney condition. The drug is now the first therapy approved in the US for focal segmental glomerulosclerosis (FSGS). The pill may be taken ...
AI Summary: The FDA approved Filspari for focal segmental glomerulosclerosis (FSGS), delivering the first specifically authorized treatment for this rare kidney disease. The approval provides a targeted therapeutic option for patients and marks a commercial milestone for Travere, raising hopes for better outcomes while spotlighting questions about access, pricing, and long‑term real‑world effectiveness.
One lot of Xanax recalled nationwide over quality issue, FDA says
medicalxpress - A widely used anxiety medication is being pulled from shelves due to "failed dissolution specifications," the U.S. Food and Drug Administration (FDA) said.
AI Summary: Regulators have flagged a quality issue and a manufacturer has recalled a specific lot of Xanax nationwide. Pharmacies and patients have been advised to check lot numbers and return affected pills; health officials emphasize the recall is precautionary, urging anyone with concerns to consult their pharmacist or clinician rather than panic-buy substitutes.
FDA to review whether to allow more access to certain peptides
medicalxpress - The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.
AI Summary: The FDA is moving toward expanding access to certain compounded peptides, opening a regulatory review that could loosen limits on how pharmacies and clinics obtain and prepare these popular therapies. The review balances potential patient demand and shortages against safety and quality-control concerns, putting compounding practices squarely under the spotlight.
Anti-amyloid Alzheimer's drugs show no clinically meaningful effect
medicalxpress - Drugs that target amyloid beta proteins in the brain likely have no clinically meaningful positive effects, while increasing the risk of bleeding and swelling in the brain, a new review in the Cochrane Database of Systematic Reviews has found.
AI Summary: A major review concludes anti-amyloid Alzheimer’s medications show no clinically meaningful effect on patients’ cognition or daily function, prompting renewed debate about drug approvals, prescribing and research priorities. The analysis calls for careful reassessment of treatment value, clearer communication to patients and tighter scrutiny of future trials.
- Anti-amyloid drugs fall short: little benefit, safety risks (5)
- New biomarkers and imaging reshape Alzheimer’s diagnosis timing (3)
- Social and care issues: loneliness, memory and treatment decisions (2)
- All Other Stories
Anti-amyloid drugs fall short: little benefit, safety risks
New biomarkers and imaging reshape Alzheimer’s diagnosis timing
Social and care issues: loneliness, memory and treatment decisions
All Other Stories
New Bill Seeks to Lower Out-of-Pocket Drug Costs
Marissa Plescia / medcitynews - Rep. Greg Murphy introduced a bill that would require out-of-pocket prescription drug spending to count toward patients’ deductibles and out-of-pocket maximums regardless of where the drugs are purchased.The post New Bill Seeks to Lower Out-of-Pocket Drug…
AI Summary: Lawmakers introduced legislation to reduce out‑of‑pocket drug costs by allowing patients' direct drug purchases to count toward their insurance deductibles. The proposal aims to ease financial strain for people buying costly medications out‑of‑pocket, but would require insurers and pharmacy systems to change longstanding accounting and benefits practices.
New drug doubles 1-year survival in pancreatic cancer trial
medicalxpress - Pancreatic cancer is one of the deadliest cancers and among the hardest to treat, with most patients surviving less than a year after diagnosis. But a new drug developed at Northwestern University may soon help patients live longer.
AI Summary: A Phase 3 study showed a novel agent markedly lengthened survival for people with metastatic pancreatic cancer, roughly doubling one-year survival versus standard care. The results, from the RASolute 302 program evaluating daraxonrasib/Revolution Medicines’ approach, represent an uncommon advance in a stubbornly lethal disease and could change treatment standards pending regulatory review.
- Clinicians celebrate landmark KRAS win; cautious optimism prevails (7)
- Daraxonrasib Phase 3: drug doubles one-year survival (5)
- Market scramble: Revolution Medicines' fundraising and buyout buzz (3)
- Other pancreatic research, methods and early-stage KRAS studies (5)
- All Other Stories
Clinicians celebrate landmark KRAS win; cautious optimism prevails
Daraxonrasib Phase 3: drug doubles one-year survival
Market scramble: Revolution Medicines' fundraising and buyout buzz
Other pancreatic research, methods and early-stage KRAS studies
All Other Stories
Experimental drug cuts Parkinson's-linked protein up to 60% in early trial
medicalxpress - An experimental drug designed to silence a gene strongly linked to Parkinson's disease has shown encouraging effects in a first-in-human clinical trial, according to a study published in Nature Medicine. The drug, known as BIIB094, targets LRRK2, the most…
AI Summary: An experimental therapeutic cut levels of a Parkinson’s‑linked protein by up to 60% in an early human study, while complementary preclinical work identified a compound that clears toxic Parkinson’s proteins from brain tissue. The twin findings hint at disease‑modifying potential, though meaningful clinical benefit and long‑term safety remain to be demonstrated.
Insmed shelves Brinsupri in skin disease after mid-stage flop
Elizabeth Cairns / endpoints - Insmed has given up on Brinsupri in the painful skin disorder hidradenitis suppurativa (HS) after a mid-stage trial failure. The company had ditched the pill in sinus inflammation at the end of last year. The ...
AI Summary: Insmed announced it will halt development of Brinsupri for a dermatologic indication following disappointing mid‑stage trial results. Company commentary stressed the skin setback does not negate Brinsupri’s potential in pulmonary indications, but investors and clinicians will understandably ask for clearer signs of life before buying the comeback story.
High-dose Wegovy debuts at $399 for self-paying patients
Paige Twenter / beckershospitalreview - Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…
AI Summary: Novo Nordisk has introduced a higher‑dose formulation of Wegovy (semaglutide) in the U.S., offering self‑pay patients access at a $399 monthly price. The rollout reflects growing demand for GLP‑1 therapies and fuels ongoing debates about affordability, access and how much of weight‑management care should depend on out‑of‑pocket spending.
- On scene: industry shifts, IPOs, stigma and miscellaneous reports (4)
- On site: Novo rolls out Wegovy HD, sparking access debates (7)
- Regulators press for more GLP-1 safety data and oversight (4)
- Reporting from clinics: GLP-1s vary in effect, risk muscle loss (9)
- All Other Stories
On scene: industry shifts, IPOs, stigma and miscellaneous reports
On site: Novo rolls out Wegovy HD, sparking access debates
Regulators press for more GLP-1 safety data and oversight
Reporting from clinics: GLP-1s vary in effect, risk muscle loss
All Other Stories
Scientists finally uncover why promising cancer drugs keep failing
sciencedaily - Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don’t actually do the same job. Instead, BRD2 acts l…
AI Summary: Scientists uncovered a cellular survival mechanism that helps tumors withstand DNA damage, offering a concrete explanation for why numerous promising anti‑cancer agents stumble in clinical trials. The discovery exposes a resistance pathway that blunts drug efficacy and suggests new targets to sensitize tumors and potentially revive stalled therapies — which, yes, might finally save some development budgets.
- BET inhibitor paradox — BRD2 preps, BRD4 triggers gene activation (3)
- OTHER — Diverse resistance mechanisms and maps of tumor adaptation (6)
- Replication-fork rescue — Tumors patch DNA breaks to survive therapy (3)
- RNA regulation vulnerabilities — RNA editing and noncoding RNAs expose targets (3)
- All Other Stories
BET inhibitor paradox — BRD2 preps, BRD4 triggers gene activation
OTHER — Diverse resistance mechanisms and maps of tumor adaptation
Replication-fork rescue — Tumors patch DNA breaks to survive therapy
RNA regulation vulnerabilities — RNA editing and noncoding RNAs expose targets
All Other Stories
Gilead Activates Its Pipeline: Option Exercises at Cartography Bio and Kymera Signal Accelerating Oncology Execution
oncodaily - In a pair of announcements that underscore Gilead Sciences’ intensifying commitment to oncology, two of its collaboration partners, Cartography Biosciences and Kymera Therapeutics, revealed today that Gilead has exercised exclusive […]
AI Summary: Gilead moved to accelerate its oncology strategy by exercising option agreements with smaller biotech partners, including Kymera and Cartography Bio. The moves signal targeted investment in protein degraders and other novel modalities, shoring up the company’s mid‑stage pipeline and hinting that big pharma still prefers buying options to inventing overnight.
Oricell Lands $110M to Take Cell Therapy to New Territory in Cancer
Frank Vinluan / medcitynews - There are no FDA-approved therapies for GPC3, a protein highly expressed by liver cancers. Oricell Therapeutics claims its cell therapy could be best in this class, but it faces competition from companies such as AstraZeneca and Eureka Therapeutics. The p…
AI Summary: Oricell, a China‑based CAR‑T developer, secured fresh financing to accelerate its cell‑therapy programs and support plans to go public. The fundraising will bankroll clinical expansion, manufacturing scale‑up, and regulatory preparations as the company pushes toward broader development and an IPO ambition, positioning it to compete in the crowded CAR‑T market.
FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer
esmo - Evidence for efficacy is based on the findings from the ROSELLA study
AI Summary: The FDA granted marketing authorization for relacorilant in combination with nab‑paclitaxel to treat platinum‑resistant epithelial ovarian, fallopian tube and primary peritoneal cancers. Regulators cited clinical benefit in a difficult‑to‑treat population, providing an additional therapeutic option for patients with limited choices and marking an important regulatory milestone.
James P. Allison, PhD, FAACR, Honored With the 2026 AACR Award for Lifetime Achievement in Cancer Research
oncodaily - James P. Allison has been honored with the 2026 AACR Award for Lifetime Achievement in Cancer Research, a distinction recognizing his extraordinary scientific achievements and enduring impact on modern oncology. […]
AI Summary: James P. Allison received the 2026 AACR Award for Lifetime Achievement in Cancer Research for pioneering work in cancer immunotherapy. The award recognizes decades of transformative science that helped establish immune‑checkpoint blockade as a foundational cancer treatment, altering therapeutic strategies across multiple tumor types.
Antoni Ribas, MD, PhD, FAACR, Honored With the 2026 AACR-Margaret Foti Award
oncodaily - The American Association for Cancer Research (AACR) has named Antoni Ribas as the recipient of the 2026 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research, recognizing a […]
AI Summary: Antoni Ribas was honored with the AACR‑Margaret Foti Award in recognition of leadership and major contributions to cancer research. The award spotlights Ribas’ influence on immunotherapy development and cancer science translation, celebrating a career that has shaped both scientific agendas and clinical practice.